Fibrinogen-to-Albumin Ratio as a Novel Predictor of Intracerebral Hemorrhage in Maintenance Hemodialysis Patients

纤维蛋白原与白蛋白比值作为维持性血液透析患者脑出血的新型预测指标

阅读:1

Abstract

OBJECTIVE: Intracerebral hemorrhage (ICH) is a life-threatening complication in patients undergoing maintenance hemodialysis (MHD), yet reliable biomarkers for early risk stratification remain scarce. The fibrinogen-to-albumin ratio (FAR), a composite inflammatory and nutritional marker, may offer predictive value for ICH in this high-risk population. METHODS: This retrospective study analyzed a total of 536 MHD patients (ICH group: n=207; non-ICH group: n=329) from June 2019 to June 2024. FAR was calculated based on laboratory parameters. Multivariate Logistic regression analysis was used to identify independent risk factors for ICH, and ROC curve analysis and restricted cubic spline (RCS) modeling were used to assess the predictive performance of FAR for cerebral hemorrhage in maintenance hemodialysis patients. Finally, the DeLong test was used to compare the differences in area under curve (AUC). RESULTS: Logistic regression analysis revealed that FAR ([OR] 1.07, 95% [CI] 1.03-1.10, p<0.001) was the independent predictor of ICH. Trend testing showed a dose-response correlation between FAR (p for trend <0.001) and ICH risk. RCS showed a non-linear correlation between FAR and ICH risk (non-linear p=0.029). ROC analysis demonstrated FAR's superior accuracy (AUC=0.75) compared to fibrinogen (AUC=0.67) and albumin (AUC=0.49), identifying 12.2 as the optimal cutoff (sensitivity=0.73, specificity=0.60). The DeLong's test confirm that FAR exhibits significantly superior discriminatory performance. CONCLUSION: FAR may predict the occurrence of ICH in MHD patients. This study explores the application value of FAR in predicting ICH risk in MHD patients, providing a new biomarker for early identification of high-risk patients in clinical practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。